Anti-CD5 CAR T cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells”In the company’s words, NCT04594135 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.”In the company’s words, NCT04594135 on ClinicalTrials.gov
Other drugs for T-cell Acute Lymphoblastic Leukemia
- WU-CART-007Allotera Therapeutics · Phase 2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/GPRC5D dual-target CAR-TBeijing Biotech · Phase 1/2
- Autologous CD19/CD20 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous CD19/CD22 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 30 Nov 2023 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026